Hepatic encephalopathy (HE) is a common complication in patients with advanced liver disease. It is a brain dysfunction characterized by neurological and psychiatric symptoms that significantly affects quality of life, morbidity and mortality of patients. HE has various precipitants that can potentially promote its onset, alone or in combination. Among the historically well-known precipitants, such as infections, gastrointestinal bleeding, dehydration, electrolyte disorders and constipation, recent studies have highlighted the role of malnutrition and portosystemic shunts as new precipitating factors of HE. The identification, management and correction of these factors are fundamental for effective HE treatment, in addition to pharmacological therapy with non-absorbable disaccharides and/or antibiotics.
Old and new precipitants in hepatic encephalopathy: a new look at a field in continuous evolution / Bellafante, Daniele; Gioia, Stefania; Faccioli, Jessica; Riggio, Oliviero; Ridola, Lorenzo; Nardelli, Silvia. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 12:3(2023), pp. 1-14. [10.3390/jcm12031187]
Old and new precipitants in hepatic encephalopathy: a new look at a field in continuous evolution
Daniele Bellafante;Stefania Gioia;Jessica Faccioli;Oliviero Riggio;Lorenzo Ridola;Silvia Nardelli
2023
Abstract
Hepatic encephalopathy (HE) is a common complication in patients with advanced liver disease. It is a brain dysfunction characterized by neurological and psychiatric symptoms that significantly affects quality of life, morbidity and mortality of patients. HE has various precipitants that can potentially promote its onset, alone or in combination. Among the historically well-known precipitants, such as infections, gastrointestinal bleeding, dehydration, electrolyte disorders and constipation, recent studies have highlighted the role of malnutrition and portosystemic shunts as new precipitating factors of HE. The identification, management and correction of these factors are fundamental for effective HE treatment, in addition to pharmacological therapy with non-absorbable disaccharides and/or antibiotics.File | Dimensione | Formato | |
---|---|---|---|
Bellafonte_Old_2023.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
321.04 kB
Formato
Adobe PDF
|
321.04 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.